Before you prescribe PrEP
The resources below provide information on how to identify HIV risk in different patient groups, standard diagnostic testing and key information to discuss with your patient before initiating PrEP. Guidelines for monitoring potential side effects related to kidney and bone health are also addressed.
This presentation explores how to identify HIV risk in patients. What are markers of elevated HIV risk that might make a patient a good candidate for PrEP? This presentation includes specific tools and markers that can be used for identifying HIV risk in different patient groups.
This presentation reviews key information to discuss with your patient prior to starting PrEP, including discussing adherence, STIs and sexual health while using PrEP, potential side effects, and ongoing care while using PrEP.
Tenofovir disoproxil fumarate has been linked to reduced kidney functions in some patients. This presentation reviews the research on tenofovir disoproxil fumarate’s impact on kidney health, how to screen and monitor kidney health in patients starting or taking TDF as PrEP, and when to discontinue use of TDF.
Tenofovir disoproxil fumarate has been linked to reduced bone density in some patients. This presentation reviews the research on tenofovir disoproxil fumarate’s impact on bone health, how to screen and monitor bone health in patients starting or taking TDF as PrEP, and management of osteopenia and osteoporosis.
This website provides general information about Pre-Exposure Prophylaxis for HIV. This site is not intended to be a substitute for professional medical advice, diagnosis, or treatment. We strongly urge individuals considering starting PrEP to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature.